RPBIF Documents déposés auprès de la SEC - Response Biomedical Corp.- Rapport annuel, procuration, prospectus

Statistiques de base

CIK

806888

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Response Biomedical Corp.

SEC Filings (Chronological Order)

Cette page fournit une liste complète et chronologique des documents déposés auprès de la SEC, à l'exclusion des documents relatifs à la participation que nous fournissons ailleurs.

December 2, 2016	15-12G	Response Biomedical FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-50571 Response Biomedical Corp. (Exact name of registrant as specified
December 2, 2016	EX-99.1	Response Biomedical Corp. Completes Going-Private Transaction ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Completes Going-Private Transaction VANCOUVER, B.C., November 29, 2016 - Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) is pleased to announce that the previously announced acquisition of all the issued and outstanding common shares of Response (?Response Shares?) by 1077801 B.C. Ltd., a company beneficially owned by
December 2, 2016	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events rpbif201611298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 29, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
December 1, 2016	S-8 POS	Response Biomedical FORM S-8 POS rpbif20161129s8pos.htm As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-211494 Registration No. 333-189470 Registration No. 333-183457 Registration No. 333-146900 Registration No. 333-126275 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statement No. 333-211494 Form S-8 R
December 1, 2016	S-8 POS	Response Biomedical FORM S-8 POS S-8 POS 1 rpbif20161129bs8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-211494 Registration No. 333-189470 Registration No. 333-183457 Registration No. 333-146900 Registration No. 333-126275 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statement N
December 1, 2016	S-8 POS	Response Biomedical FORM S-8 POS rpbif20161129s8pos.htm As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-211494 Registration No. 333-189470 Registration No. 333-183457 Registration No. 333-146900 Registration No. 333-126275 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statement No. 333-211494 Form S-8 R
December 1, 2016	S-8 POS	Response Biomedical FORM S-8 POS S-8 POS 1 rpbif20161129ds8pos.htm FORM S-8 POS As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-211494 Registration No. 333-189470 Registration No. 333-183457 Registration No. 333-146900 Registration No. 333-126275 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statement N
December 1, 2016	S-8 POS	Response Biomedical FORM S-8 POS rpbif20161129s8pos.htm As filed with the Securities and Exchange Commission on November 30, 2016 Registration No. 333-211494 Registration No. 333-189470 Registration No. 333-183457 Registration No. 333-146900 Registration No. 333-126275 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO Form S-8 Registration Statement No. 333-211494 Form S-8 R
December 1, 2016	SC 13D/A	RPBIF / Response Biomedical Corp. / ORBIMED ADVISORS LLC - AMENDMENT NO. 9 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Response Biomedical Corp. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 76123L303 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Limited OrbiMed Asia GP, L.P. OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexingt
December 1, 2016	EX-99.N	JOINT FILING AGREEMENT Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 9, 2010, as amended by Amendment No.
November 30, 2016	SC 13E3/A	RPBIF / Response Biomedical Corp. / Response Biomedical Corp - SCHEDULE 13E3/A rpbif20161129sc13e3a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 4) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Response Biomedical Corp. Samuel D. Isaly 1077801 B.C. Ltd. Orbimed Asia Partners, L.P Orbimed Private Investments III,
November 15, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2016 RESPONSE BIOMEDICAL CORP.
November 15, 2016	EX-99.1	Response Biomedical Corp. Announces Third Quarter 2016 Financial Results and Update on Going-Private Transaction ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Third Quarter 2016 Financial Results and Update on Going-Private Transaction VANCOUVER, British Columbia ? November 10, 2016 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financia
November 14, 2016	10-Q	Response Biomedical FORM 10-Q (Quarterly Report) 10-Q 1 rpbif2016090110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2016  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C
September 21, 2016	EX-99.2	Response Biomedical Corp. Receives Court Approval of Going-Private Transaction ex99-2.htm Exhibit 99.2 Response Biomedical Corp. Receives Court Approval of Going-Private Transaction VANCOUVER, B.C., September 19, 2016 - Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) is pleased to announce that the Supreme Court of British Columbia has approved the previously announced acquisition of all the issued and outstanding common shares of Response by 1
September 21, 2016	EX-99.1	Response Biomedical Corp. Receives Shareholder Approval of Going-Private Transaction ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Receives Shareholder Approval of Going-Private Transaction VANCOUVER, B.C., September 16, 2016 - Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) is pleased to announce that the previously announced acquisition of all the issued and outstanding common shares of Response (?Response Shares?) by 1077801 B.C. Ltd., a compa
September 21, 2016	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 rpbif201609208k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1
August 16, 2016	DEFA14A	Response Biomedical FORM DEFA14A rpbif20160815defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by
August 16, 2016	DEFA14A	Response Biomedical FORM DEFA14A rpbif20160815defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by
August 16, 2016	EX-99.1	Response Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of Shareholders ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of Shareholders VANCOUVER, British Columbia ? August 12, 2016 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of c
August 16, 2016	EX-99.1	Response Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of Shareholders ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Second Quarter 2016 Financial Results and Filing of Definitive Proxy Statement for Special Meeting of Shareholders VANCOUVER, British Columbia ? August 12, 2016 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of c
August 16, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rpbif201608158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042
August 16, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rpbif201608158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 12, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042
August 15, 2016	10-Q	Response Biomedical FORM 10-Q (Quarterly Report) rpbif2016063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
August 15, 2016	10-Q	Response Biomedical FORM 10-Q (Quarterly Report) rpbif2016063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
August 11, 2016	DEFM14A	Response Biomedical FORM DEFM14A rpbif20160623def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 11, 2016	SC 13E3/A	RPBIF / Response Biomedical Corp. / Response Biomedical Corp - SCHEDULE 13E3/A rpbif20160623sc13e3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 3) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Response Biomedical Corp. Samuel D. Isaly 1077801 B.C. Ltd. OrbiMed Asia Partners, L.P. OrbiMed Private Investments III,
August 4, 2016	PRER14A	Response Biomedical FORM PRER14A rpbif20160623def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
August 4, 2016	CORRESP	Response Biomedical ESP rpbif20160804corresp.htm 12235 El Camino Real, Suite 200 San Diego, CA 92130-3002 PHONE 858.350.2300 FAX 858.350.2399 www.wsgr.com August 4, 2016 VIA EDGAR AND COURIER Mr. John Reynolds Assistant Director Division of Corporation Finance United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, D.C. 20549-6010 Re: Response Biomedica
August 4, 2016	SC 13E3/A	RPBIF / Response Biomedical Corp. / Response Biomedical Corp - SCHEDULE 13E3/A rpbif20160623sc13e3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 2) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Response Biomedical Corp. Samuel D. Isaly 1077801 B.C. Ltd. OrbiMed Asia Partners, L.P. OrbiMed Private Investments III,
July 25, 2016	PRER14A	Response Biomedical FORM PRER14A rpbif20160623def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
July 25, 2016	SC 13E3/A	RPBIF / Response Biomedical Corp. / Response Biomedical Corp - SCHEDULE 13E3/A rpbif20160623sc13e3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) (Amendment No. 1) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Response Biomedical Corp. Samuel D. Isaly 1077801 B.C. Ltd. OrbiMed Asia Partners, L.P. OrbiMed Private Investments III,
July 25, 2016	CORRESP	Response Biomedical ESP rpbif20160725corresp.htm 12235 El Camino Real, Suite 200 San Diego, CA 92130-3002 PHONE 858.350.2300 FAX 858.350.2399 www.wsgr.com July 25, 2016 VIA EDGAR AND COURIER Mr. John Reynolds Assistant Director Division of Corporation Finance United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Mail Stop 3561 Washington, D.C. 20549-6010 Re: Response Biomedical
June 27, 2016	EX-99.C2	EX-99.C2 ex99-c2.htm Exhibit (c)(2)
June 27, 2016	EX-99.D2	Form of Voting and Support Agreement ex99-d2.htm Exhibit (d)(2) Form of Voting and Support Agreement , 2016 PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Voting and Support Agreement Dear : As you know, OrbiMed Advisors LLC and Shanghai Runda Medical Technology Co., Ltd., through 1077801 B.C. Ltd. (the “Purchaser”) have been in discussions with the board of directors of Response Biomedical Corp. (“Response”) regarding a proposed transaction
June 27, 2016	EX-99.D3	Rollover Agreement ex99-d3.htm Exhibit (d)(3) Rollover Agreement , PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Rollover in connection with the Arrangement Agreement between 1077801 B.C. Ltd. and Response Biomedical Corp. Dear Sirs/Mesdames: This letter agreement (this “Agreement”) sets forth the commitment of the undersigned (the “Company Securityholder”), subject to the terms and conditions contained herein, to transfer
June 27, 2016	SC 13E3	RPBIF / Response Biomedical Corp. / Response Biomedical Corp - SCHEDULE 13E3 rpbif20160623sc13e3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) Rule 13e-3 Transaction Statement Under Section 13(e) of the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Response Biomedical Corp. 1077801 B.C. LTD. Orbimed Asia Partners, L.P Orbimed Private Investments III, LP Orbimed Associates III, LP Shang
June 24, 2016	PREM14A	Response Biomedical FORM PREM14A rpbif20160623def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
June 20, 2016	EX-10.1	SUBSCRIPTION AGREEMENT ex10-1.htm Exhibit 10.1 SUBSCRIPTION AGREEMENT TO: RESPONSE BIOMEDICAL CORP. The undersigned (referred to herein as the ?Purchaser?), hereby irrevocably subscribes to purchase from Response Biomedical Corp. (the ?Issuer?) the number of common shares (the ?Purchased Securities? and each individually, a ?Purchased Security?) of the Issuer set out below for a subscription price of US$0.56 per Purchas
June 20, 2016	EX-99.1	Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement VANCOUVER, B.C., June 16, 2016 ? Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) announces that it has entered into a definitive arrangement agreement (the ?Arrangement Agreement?) with 1077801 B.C. Ltd., a company owned by OrbiMed A
June 20, 2016	EX-2.1	1077801 b.c. lTD. RESPONSE BIOMEDICAL CORP. ARRANGEMENT AGREEMENT June 16, 2016 ex2-1.htm Exhibit 2.1 1077801 b.c. lTD. and RESPONSE BIOMEDICAL CORP. ARRANGEMENT AGREEMENT June 16, 2016 TABLE OF CONTENTS ARTICLE1 INTERPRETATION Section 1.1 Defined Terms. 1 Section 1.2 Certain Rules of Interpretation. 11 ARTICLE 2 THE ARRANGEMENT Section 2.1 Arrangement 13 Section 2.2 Interim Order 13 Section 2.3 The Company Meeting 14 Section 2.4 The Company Circular 16 Section 2.5 Final Orde
June 20, 2016	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201606178k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or oth
June 20, 2016	EX-2.1	1077801 b.c. lTD. RESPONSE BIOMEDICAL CORP. ARRANGEMENT AGREEMENT June 16, 2016 ex2-1.htm Exhibit 2.1 1077801 b.c. lTD. and RESPONSE BIOMEDICAL CORP. ARRANGEMENT AGREEMENT June 16, 2016 TABLE OF CONTENTS ARTICLE1 INTERPRETATION Section 1.1 Defined Terms. 1 Section 1.2 Certain Rules of Interpretation. 11 ARTICLE 2 THE ARRANGEMENT Section 2.1 Arrangement 13 Section 2.2 Interim Order 13 Section 2.3 The Company Meeting 14 Section 2.4 The Company Circular 16 Section 2.5 Final Orde
June 20, 2016	EX-99.1	Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Enters into Definitive Agreements for Going-Private Transaction and Private Placement VANCOUVER, B.C., June 16, 2016 ? Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) announces that it has entered into a definitive arrangement agreement (the ?Arrangement Agreement?) with 1077801 B.C. Ltd., a company owned by OrbiMed A
June 20, 2016	EX-10.1	SUBSCRIPTION AGREEMENT ex10-1.htm Exhibit 10.1 SUBSCRIPTION AGREEMENT TO: RESPONSE BIOMEDICAL CORP. The undersigned (referred to herein as the ?Purchaser?), hereby irrevocably subscribes to purchase from Response Biomedical Corp. (the ?Issuer?) the number of common shares (the ?Purchased Securities? and each individually, a ?Purchased Security?) of the Issuer set out below for a subscription price of US$0.56 per Purchas
June 20, 2016	DEFA14A	Response Biomedical FORM 8-K rpbif201606178k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or oth
June 20, 2016	SC 13D/A	RPBIF / Response Biomedical Corp. / ORBIMED ADVISORS LLC - AMENDMENT NO. 8 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Response Biomedical Corp. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 76123L303 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Limited OrbiMed Asia GP, L.P. OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexingt
June 20, 2016	EX-99.U	Rollover Agreement Exhibit U Rollover Agreement June 16, 2016 PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Rollover in connection with the Arrangement Agreement between 1077801 B.
June 20, 2016	EX-99.V	Rollover Agreement Exhibit V Rollover Agreement June 16, 2016 PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Rollover in connection with the Arrangement Agreement between 1077801 B.
June 20, 2016	EX-99.P	SUBSCRIPTION AGREEMENT Exhibit P SUBSCRIPTION AGREEMENT TO: RESPONSE BIOMEDICAL CORP. The undersigned (referred to herein as the “Purchaser”), hereby irrevocably subscribes to purchase from Response Biomedical Corp. (the “Issuer”) the number of common shares (the “Purchased Securities” and each individually, a “Purchased Security”) of the Issuer set out below for a subscription price of US$0.56 per Purchased Security (t
June 20, 2016	EX-99.Q	SUBSCRIPTION AGREEMENT Exhibit Q SUBSCRIPTION AGREEMENT TO: RESPONSE BIOMEDICAL CORP. The undersigned (referred to herein as the “Purchaser”), hereby irrevocably subscribes to purchase from Response Biomedical Corp. (the “Issuer”) the number of common shares (the “Purchased Securities” and each individually, a “Purchased Security”) of the Issuer set out below for a subscription price of US$0.56 per Purchased Security (t
June 20, 2016	EX-99.N	JOINT FILING AGREEMENT Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 9, 2010, as amended by Amendment No.
June 20, 2016	EX-99.T	Rollover Agreement Exhibit T Rollover Agreement June 16, 2016 PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Rollover in connection with the Arrangement Agreement between 1077801 B.
June 20, 2016	EX-99.S	Form of Voting and Support Agreement Exhibit S Form of Voting and Support Agreement , 2016 PRIVATE AND CONFIDENTIAL VIA EMAIL Re: Voting and Support Agreement Dear : As you know, OrbiMed Advisors LLC and Shanghai Runda Medical Technology Co.
June 20, 2016	EX-99.R	SUBSCRIPTION AGREEMENT Exhibit R SUBSCRIPTION AGREEMENT TO: RESPONSE BIOMEDICAL CORP. The undersigned (referred to herein as the “Purchaser”), hereby irrevocably subscribes to purchase from Response Biomedical Corp. (the “Issuer”) the number of common shares (the “Purchased Securities” and each individually, a “Purchased Security”) of the Issuer set out below for a subscription price of US$0.56 per Purchased Security (t
June 15, 2016	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201606158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 13, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or oth
June 15, 2016	EX-99.1	Response Biomedical Corp. Announces Voting Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Voting Results VANCOUVER, B.C., June 13, 2016 - Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF), in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2016 Annual General and Special Meeting of Shareholders held earlier today. A total of 6,110,
May 31, 2016	EX-1.01	Conflict Minerals Report of Response Biomedical Corp. ex1-01.htm Exhibit 1.01 Conflict Minerals Report of Response Biomedical Corp. This is the Conflict Minerals Report for Response Biomedical Corp. (?Response Biomedical?) for calendar year 2015 in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (?Rule 13p-1?). In accordance with Rule 13p-1, Response Biomedical undertook due diligence to determine whether the conflict minerals us
May 31, 2016	SD	Response Biomedical FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS. Employer Identification No.) 1781 - 75th Avenue W. Vancouver, British Col
May 20, 2016	S-8	Response Biomedical FORM S-8 rpbif20160519s8.htm As filed with the Securities and Exchange Commission on May 20, 2016 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 RESPONSE BIOMEDICAL CORP. (Exact name of Registrant as specified in its charter) Vancouver, British Columbia, Canada 98-1042523 (State or other jurisdic
May 19, 2016	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rpbif201605198k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 16, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523
May 19, 2016	EX-99.1	Response Biomedical Corp. Announces First Quarter 2016 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces First Quarter 2016 Financial Results VANCOUVER, British Columbia – May 16, 2016 - Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its first quarter ended March 3
May 16, 2016	10-Q	Response Biomedical FORM 10-Q (Quarterly Report) 10-Q 1 rpbif2016033110q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2016 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss
May 12, 2016	DEF 14A	Response Biomedical FORM DEF 14A rpbif20160512def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
April 29, 2016	10-K/A	Response Biomedical FORM 10-K/A (Annual Report) rpbif2016042910ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file n
March 24, 2016	10-K	Response Biomedical FORM 10-K (Annual Report) rpbif2015123110k.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50571 RESPONS
March 24, 2016	EX-21	List of Worldwide Subsidiaries of Response Biomedical Corp. as of ex21.htm Exhibit 21 List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 24, 2016 Structure of ownership and control: Response Biomedical Corp. wholly owns the below mentioned entity. Subsidiary Name Jurisdiction of Organization Response Point of Care Inc. Delaware Response Biomedical Inc. (Inactive) Washington
March 24, 2016	EX-10.37	EXECUTIVE EMPLOYMENT AGREEMENT ex10-37.htm Exhibit 10.37 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of December 22, 2015. BETWEEN: RESPONSE BIOMEDICAL CORP. (the “Company”), having an office at 1781 West 75th Ave., Vancouver, BC, Canada V6P 6P2, AND DR. BARBARA KINNAIRD, (the “Executive”), having a residence at 15 - 6333 Princess Lane, Richmond, BC, V7E 6T3 WHEREAS: A. The Company wishes to promote the E
March 23, 2016	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201603228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 21, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
March 23, 2016	EX-99.1	Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2015 Financial Results VANCOUVER, British Columbia ? March 21, 2016 - Response Biomedical Corp. (?Response? or the ?Company?) (TSX: RBM, OTC: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its fourth quarte
January 13, 2016	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201601138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 12, 2016 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
December 10, 2015	EX-99.1	Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi ex99-1.htm Exhibit 99.1 Response Biomedical Announces Strategic Alliances in Japan with Alere Medical and Long Time Partner Shionogi VANCOUVER, British Columbia ? December 8, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF), a commercial stage in-vitro diagnostics company with products for the laboratory and point of care markets, today reported a restructuri
December 10, 2015	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201512098k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 24, 2015	EX-99.1	Response Biomedical Corp. Announces Notification of TSX Continued Listing Review ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Notification of TSX Continued Listing Review VANCOUVER, British Columbia ? November 19, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today announced that it has received notice that the
November 24, 2015	8-K	Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events rpbif201511248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 18, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 16, 2015	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 rpbif201511168k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 12, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -10
November 16, 2015	EX-99.1	Response Biomedical Corp. Announces Third Quarter 2015 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Third Quarter 2015 Financial Results VANCOUVER, British Columbia ? November 12, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF) a commercial stage in-vitro medical device company with products for the laboratory and point of care markets, today reported financial results for its third quarter and ni
November 13, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 Respons
August 18, 2015	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201508178k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 14, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
August 18, 2015	EX-99.1	Response Biomedical Corp. Announces Second Quarter 2015 Financial Results ex99-1.htm Exhibit 99.1 August 14, 2015 Response Biomedical Corp. Announces Second Quarter 2015 Financial Results VANCOUVER, British Columbia ? August 14, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF) today reported financial results for its second quarter and six months ended June 30, 2015 including a 39% increase in total revenue, a 16% increase in produ
August 14, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table Of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-
June 15, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8-K 1 rpbif201506158k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 9, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523
June 2, 2015	EX-10.1	COLLABORATION AGREEMENT RESPONSE BIOMEDICAL CORP. HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD. Dated as of February16, 2015 EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 COLLABORATION AGREEMENT Between RESPONSE BIOMEDICAL CORP. and HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD. Dated as of February16, 2015 1 Content RECITALS 3 ARTICLE 1 DEFINITIONS 4 ARTICLE 2 CO-DEVELOPMENT AND COLLABORATION 8 ARTICLE 3 JOINT STEERING COMMITTEE 12 ARTICLE 4 JOINT DEVELOPMENT COMMITTEE 14 ARTICLE 5 PAYMENT OBLIGATIONS 15 ARTICLE 6
June 2, 2015	8-K/A	Response Biomedical FORM 8-K/A (Current Report/Significant Event) rpbif201505298ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571
June 2, 2015	EX-10.2	SUPPLY AGREEMENT ex10-2.htm Exhibit 10.2 SUPPLY AGREEMENT This Supply Agreement (this ?Agreement?), dated as of February 16, 2015 (the ?Effective Date?), is between RESPONSE BIOMEDICAL CORP., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (?Response?), and ??????????????, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Main Building
June 1, 2015	SD	Response Biomedical FORM SD rpbif20150601sd.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS. Employer Identification No.) 1781 - 75th Avenue W. Va
June 1, 2015	EX-1.01	Conflict Minerals Report of Response Biomedical Corp. ex1-01.htm Exhibit 1.01 Conflict Minerals Report of Response Biomedical Corp. This is the Conflict Minerals Report for Response Biomedical Corp. (?Response Biomedical?) for calendar year 2014 in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (?Rule 13p-1?). In accordance with Rule 13p-1, Response Biomedical undertook due diligence to determine whether the conflict minerals us
May 21, 2015	EX-99.1	Response Biomedical Corp. Announces the Appointment of Dr. Barbara Kinnaird Ph.D. as Chief Executive Officer and Voting Results from its 2015 AGM ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces the Appointment of Dr. Barbara Kinnaird Ph.D. as Chief Executive Officer and Voting Results from its 2015 AGM VANCOUVER, British Columbia ? May 19, 2015 ? The Board of Directors of Response Biomedical Corp. (TSX: RBM, OTCQB: RPBIF) (?Response? or ?the Company?), is pleased to announce the promotion of Dr. Barbara Kinnaird Ph.D. to the pos
May 21, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders rpbif201505208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or othe
May 8, 2015	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201505078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other
May 8, 2015	EX-99.1	Response Biomedical Corp. Announces First Quarter 2015 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces First Quarter 2015 Financial Results VANCOUVER, British Columbia ? May 5, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF) today reported financial results for its first quarter ended March 31, 2015. ?We are pleased to report that our product revenue this quarter increased 28% over the same quarter l
May 8, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 Response Bi
April 15, 2015	DEF 14A	Response Biomedical FORM DEF 14A rpbif20150415def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 20, 2015	EX-99.1	Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2014 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2014 Financial Results VANCOUVER, British Columbia ? March 16, 2015 - Response Biomedical Corp. (?Response? or ?the Company?) (TSX: RBM, OTCQB: RPBIF) today reported financial results for the fourth quarter and year ended December 31, 2014. Response?s Interim Chief Executive Officer, Dr. Anthony (Tony) Holler, co
March 20, 2015	8-K	Response Biomedical FORM 8-K (Current Report/Significant Event) rpbif201503208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
March 19, 2015	EX-21	List of Worldwide Subsidiaries of Response Biomedical Corp. as of March Exhibit 21 List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 19, 2015 Structure of ownership and control: Response Biomedical Corp. wholly owns the below mentioned entity. Subsidiary Name Jurisdiction of Organization Response Point of Care Inc. Delaware Response Biomedical Inc. (Inactive) Washington
March 19, 2015	10-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50571 RESPONSE BIOMEDICAL CORP. (E
March 16, 2015	8-K/A	Response Biomedical FORM 8-K/A (Current Report/Significant Event) rpbif201503138ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 9
March 16, 2015	EX-10.2	Binding Term Sheet - Supply ex10-2.htm Exhibit 10.2 Binding Term Sheet - Supply Confidential This binding term sheet (this ?Binding Term Sheet?), dated as of October 15, 2014, is between Response Biomedical Corp., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (?Response?), and ??????????????, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Ma
February 20, 2015	EX-10.2	SUPPLY AGREEMENT ex10-2.htm Exhibit 10.2 SUPPLY AGREEMENT This Supply Agreement (this “Agreement”), dated as of February 16, 2015 (the “Effective Date”), is between RESPONSE BIOMEDICAL CORP., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (“Response”), and 杭州中翰盛泰生物技术有限公司, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Main Building
February 20, 2015	EX-99.1	Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration VANCOUVER, B.C., February 16, 2015 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCQB: RPBIF) today announced that it has earned the second milestone of US$720,000 in the funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Lt
February 20, 2015	EX-10.1	COLLABORATION AGREEMENT RESPONSE BIOMEDICAL CORP. HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD. Dated as of February16, 2015 Exhibit 10.1 COLLABORATION AGREEMENT Between RESPONSE BIOMEDICAL CORP. and HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD. Dated as of February16, 2015 1 Content RECITALS 3 ARTICLE 1 DEFINITIONS 4 ARTICLE 2 CO-DEVELOPMENT AND COLLABORATION 8 ARTICLE 3 JOINT STEERING COMMITTEE 12 ARTICLE 4 Joint Development Committee 14 ARTICLE 5 PAYMENT OBLIGATIONS 15 ARTICLE 6 INTELLECTUAL PROPERTY 17 ARTICLE 7
February 20, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events rpbif201502208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 16, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
February 11, 2015	EX-99	Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP® Cardiovascular Products ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP® Cardiovascular Products Vancouver, British Columbia, February 6, 2015 – Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCQB: RPBIF) today announced that it has expanded the scope of its agreement to distribute its Cardiovascular portfolio of RAMP® products with Sha
February 11, 2015	EX-10	SECOND AMENDMENT TO INTERNATIONAL DISTRIBUTION AGREEMENT ex10-1.htm Exhibit 10.1 SECOND AMENDMENT TO INTERNATIONAL DISTRIBUTION AGREEMENT This Second Amendment to International Distribution Agreement (this “Amendment”), effective as of April 23, 2015 (the “Amendment Effective Date”), is entered into between Response Biomedical Corp., having an office at 1781 – 75th Avenue West, Vancouver, BC, Canada V6P 6P2 (“Response”), and Shanghai Elite Bio Co., Ltd
February 11, 2015	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events rpbif201502108k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2015 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
January 23, 2015	EX-99.N	JOINT FILING AGREEMENT Exhibit N JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 9, 2010, as amended by Amendment No.
January 23, 2015	SC 13D/A	RPBIF / Response Biomedical Corp. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Response Biomedical Corp. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 76123L303 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Limited OrbiMed Asia GP, L.P. OrbiMed Capital GP III LLC Samuel D. Isaly 601 Lexingt
December 30, 2014	EX-10.2	Binding Term Sheet - Supply ex10-2.htm Exhibit 10.2 Binding Term Sheet - Supply Confidential This binding term sheet (this “Binding Term Sheet”), dated as of October 15, 2014, is between Response Biomedical Corp., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (“Response”), and 杭州中翰盛泰生物技术有限公司, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Ma
December 30, 2014	8-K/A	Current Report rpbif201412298ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State
December 24, 2014	EX-10.1	FORBEARANCE TO LOAN AGREEMENT ex10-1.htm Exhibit 10.1 FORBEARANCE TO LOAN AGREEMENT This FORBEARANCE TO LOAN AGREEMENT (this “Agreement”) is entered into this 31st day of October, 2014, by and between Silicon Valley Bank (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan Agreement dated as of February 11, 2014 as amended by that
December 24, 2014	8-K/A	Financial Statements and Exhibits rpbif201412238ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State
December 22, 2014	SC 13D	RLH / Red Lion Hotels Corp. / Hangzhou Joinstar Medical Instrument & Reagent Co. Ltd. - SCHEDULE 13D Activist Investment hangzhou20141222sc13d.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 Response Biomedical Corp. (Name of Issuer) Common Shares, without par value (Title of Class of Securit
December 18, 2014	EX-99	Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank EX-99 3 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank VANCOUVER, B.C., December 15, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) announced that the Company has entered into an Amendment to its existing Loan Agreement (the “Amended Loan Agreement”) with the lender under its outstanding term l
December 18, 2014	EX-10	SECOND AMENDMENT TO LOAN AGREEMENT EX-10 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECOND AMENDMENT TO LOAN AGREEMENT THIS SECOND AMENDMENT to Loan Agreement (this “Amendment”) is entered into this 15th day of December, 2014, by and between SILICON VALLEY BANK (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan Agreement dated as of Febr
December 18, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant rpbif201412178k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
December 16, 2014	EX-99	Response Biomedical Corp. Announces Closing of Private Placement ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Closing of Private Placement VANCOUVER, B.C., December 12, 2014 - Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) is pleased to announce the closing of the previously announced non-brokered private placement (the “Private Placement”) with two entities related to Hangzhou Joinstar Biomedical Technology Co.
December 16, 2014	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events rpbif201412168k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 12, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 14, 2014	8-K/A	Financial Statements and Exhibits rpbif201411148ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2014 (September 30, 2014) RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-505
November 14, 2014	EX-10	FORBEARANCE TO LOAN AGREEMENT ex10-1.htm Exhibit 10.1 FORBEARANCE TO LOAN AGREEMENT This FORBEARANCE TO LOAN AGREEMENT (this “Agreement”) is entered into this 30th day of September, 2014, by and between Silicon Valley Bank (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). RECITALS A. Bank and Borrower have entered into that certain Loan Agreement dated as of February 11, 2014 as amended by th
November 13, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q rpbif2014093010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2014 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 12, 2014	EX-99	Response Biomedical Corp. Announces Third Quarter 2014 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Third Quarter 2014 Financial Results VANCOUVER, British Columbia – November 10, 2014 - Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the third quarter and nine months ended September 30, 2014 including a 5% increase in sales compared with the same period last year. Re
November 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition rpbif201411128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 10, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 12, 2014	CORRESP	RPBIF / Response Biomedical Corp. CORRESP - - rpbif20141112corresp.htm 12235 El Camino Real, Suite 200 San Diego, CA 92130-3002 PHONE 858.350.2300 FAX 858.350.2399 www.wsgr.com November 12, 2014 VIA EDGAR AND OVERNIGHT DELIVERY Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Attention: Cecilia Blye, Chief, Office of Global Security Risk Pradip Bhaumik, Special Counsel Re: Response Bi
November 6, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events rpbif201411068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 6, 2014	EX-99	Response Biomedical Corp. Provides Update on Term Loan ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Provides Update on Term Loan VANCOUVER, B.C., November 3, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) announced that the Company has entered into a second Forbearance to Loan Agreement (the “Forbearance Agreement”) with the lender under its outstanding term loan, Silicon Valley Bank (“SVB”), as of October
November 6, 2014	EX-10	FORBEARANCE TO LOAN AGREEMENT ex10-1.htm Exhibit 10.1 FORBEARANCE TO LOAN AGREEMENT This FORBEARANCE TO LOAN AGREEMENT (this “Agreement”) is entered into this 31st day of October, 2014, by and between Silicon Valley Bank (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). Recitals A. Bank and Borrower have entered into that certain Loan Agreement dated as of February 11, 2014 as amended by that
October 21, 2014	EX-10	TECHNOLOGY DEVELOPMENT AGREEMENT EX-10 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 TECHNOLOGY DEVELOPMENT AGREEMENT This Technology Development Agreement (this “Technology Development Agreement”) is made and entered into as of October 15, 2014 (the “Effective Date”), by and between Response Biomedical Corp., a corporation organized under the laws of British Columbia and having a place of business at 1781-75th Avenue W., Vancouver, B.C
October 21, 2014	EX-99	Response Biomedical Corp. Announces Funded Program and Equity Investment by Leading Chinese Medical Device Company ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Funded Program and Equity Investment by Leading Chinese Medical Device Company VANCOUVER, B.C., October 15, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into a funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“Joins
October 21, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events rpbif201410208k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 15, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
October 21, 2014	EX-10	Binding Term Sheet - Equity Investment (JMIR) ex10-3.htm Exhibit 10.3 Binding Term Sheet - Equity Investment (JMIR) Confidential This Binding Term Sheet - Equity Investment (JMIR) (this “Binding Term Sheet”), dated as of October 15th, 2014, is between 杭州中翰盛泰医疗器械有限公司HANGZHOU Joinstar Medical INSTRUMENT & REAGENT Co., Ltd., having its registered address at Floor 1, Building 3, #519 Xingguo RD, Qianjiang Economic Development Zone, Hangzhou, Zhej
October 21, 2014	EX-10	Binding Term Sheet - Equity Investment (HZLZ) ex10-4.htm Exhibit 10.4 Binding Term Sheet - Equity Investment (HZLZ) Confidential This Binding Term Sheet - Equity Investment (HZLZ) (this “Binding Term Sheet”), dated as of October 15th, 2014, is between 杭州丽珠医疗器械有限公司Hangzhou Lizhu Medical Instrument & Reagent Co., Ltd，注册地址为2F, Building 6, #188-200, Moganshan Road, Hangzhou, Zhejiang, China (“HZLZ”) and Response Biomedical Corp., having its princ
October 21, 2014	EX-10	Binding Term Sheet - Supply ex10-2.htm Exhibit 10.2 Binding Term Sheet - Supply Confidential This binding term sheet (this “Binding Term Sheet”), dated as of October 15, 2014, is between Response Biomedical Corp., having its principle address at 1781-75th Avenue W., Vancouver, B.C., Canada V6P 6P2 (“Response”), and 杭州中翰盛泰生物技术有限公司, HANGZHOU JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD, having its registered address at Floor 10, Ma
October 6, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events rpbif201410068k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 30, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State o
October 6, 2014	EX-99	Response Biomedical Corp. Provides Update on Term Loan ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Provides Update on Term Loan VANCOUVER, B.C., October 1, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) announced that the Company has entered into a Forbearance to Loan Agreement (the “Forbearance Agreement”) with the lender under its outstanding term loan, Silicon Valley Bank (“SVB”), as of September 30, 2
October 6, 2014	EX-10	FORBEARANCE TO LOAN AGREEMENT ex10-1.htm Exhibit 10.1 FORBEARANCE TO LOAN AGREEMENT This FORBEARANCE TO LOAN AGREEMENT (this “Agreement”) is entered into this 30th day of September, 2014, by and between Silicon Valley Bank (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). RECITALS A. Bank and Borrower have entered into that certain Loan Agreement dated as of February 11, 2014 as amended by th
September 22, 2014	EX-99	Response Biomedical Corp. Announces Management Changes ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Management Changes VANCOUVER, B.C., September 16, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) announced today a series of management changes. Jeffrey Purvin has resigned from the Board of Directors and as the President and Chief Executive Officer of the Company effective immediately. He will be
September 22, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits rpbif201409228k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 16, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State o
September 2, 2014	EX-99	Response Biomedical Corp. Announces New Chairman of the Board ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces New Chairman of the Board VANCOUVER, B.C., August 28, 2014 – Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) is pleased to announce that Lewis J. “Lew” Shuster has been appointed Chairman of its board of directors (the “Board”). Dr. Peter A. Thompson, the outgoing Chairman, will remain on the Board. “Lew b
September 2, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits rpbif201408298k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 28, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
August 15, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits rpbif201408158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
August 15, 2014	EX-10	SEPARATION AGREEMENT AND RELEASE ex10-1.htm Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Timothy Patrick Shannon (“Executive”) and Response Biomedical Corp. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Executive was employed by the Company; WHEREAS, Executive signed an Executive Em
August 13, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2014  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 RESPONSE BIO
August 12, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition rpbif201408128k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 11, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
August 12, 2014	EX-99	Response Biomedical Corp. Announces Second Quarter 2014 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Second Quarter 2014 Financial Results VANCOUVER, British Columbia – August 11, 2014 - Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the second quarter and six months ended June 30, 2014 including a 12% increase in sales and improving gross margin. Response’s Chief Exe
August 6, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers rpbif201408058k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
May 30, 2014	EX-1.01	Conflict Minerals Report of Response Biomedical Corp. ex101.htm Exhibit 1.01 Conflict Minerals Report of Response Biomedical Corp. This is the Conflict Minerals Report for Response Biomedical Corp. (“Response Biomedical”) for calendar year 2013 in accordance with Rule 13p-1 under the Securities Exchange Act of 1934 (“Rule 13p-1”). In accordance with Rule 13p-1, Response Biomedical undertook due diligence to determine whether the conflict minerals use
May 30, 2014	SD	- FORM SD response20140530formsd.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other jurisdiction of incorporation) (Commission File Number) (IRS. Employer Identification No.) 1781 - 75th Avenu
May 14, 2014	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q rpbif2014033110q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2014  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number:
May 14, 2014	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K rpbif201405148k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other
May 13, 2014	EX-99	Response Biomedical Corp. Announces First Quarter 2014 Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces First Quarter 2014 Financial Results VANCOUVER, British Columbia – May 12, 2014 - Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the first quarter ended March 31, 2014 including gross margin that was essentially unchanged in spite of seasonally lower flu sales and a tr
May 13, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K rpbif201405138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 12, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or othe
May 9, 2014	8-K	Submission of Matters to a Vote of Security Holders rpbif201405088k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 8, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or other
April 15, 2014	EX-10	FIRST AMENDMENT TO LOAN AGREEMENT ex10-1.htm Exhibit 10.1 FIRST AMENDMENT TO LOAN AGREEMENT THIS FIRST AMENDMENT to Loan Agreement (this “Amendment”) is entered into this 14th day of April, 2014, by and between SILICON VALLEY BANK (“Bank”) and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”). RECITALS A. Bank and Borrower have entered into that certain Loan Agreement dated as of February 11, 2014 (as the same
April 15, 2014	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K rpbif201404148k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 14, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
April 11, 2014	DEF 14A	- FORM DEF 14A rpbif20140411def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
March 27, 2014	EX-10	LOAN AGREEMENT ex10-1.htm Exhibit 10.1 EXECUTION VERSION LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”) dated as of February 11, 2014 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as fol
March 27, 2014	8-K/A	Financial Statements and Exhibits - FORM 8-K/A rpbif201403268ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 26, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
March 17, 2014	EX-21	List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 14, 2014 Exhibit 21 List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 14, 2014 Structure of ownership and control: Response Biomedical Corp. wholly owns the below mentioned entity. Subsidiary Name Jurisdiction of Organization Response Point of Care Inc. Delaware Response Biomedical Inc. (Inactive) Washington
March 17, 2014	EX-99	Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2013 Financial Results EX-99 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2013 Financial Results VANCOUVER, British Columbia – March 13, 2014 - Response Biomedical Corp. (“Response” or “the Company”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the fourth quarter and year ended December 31, 2013 including improved margins and reduced operating cost
March 17, 2014	10-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K rpbif2013123110k.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50571 RESPONS
March 17, 2014	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K rpbif201403148k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 13, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
February 13, 2014	EX-99	Response Biomedical Corp. secures US$2.5 Million Term Loan ex99-1.htm Exhibit 99.1 Response Biomedical Corp. secures US$2.5 Million Term Loan Vancouver, British Columbia, February 11, 2014 – Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) today announced that it has secured a US$2.5 million term loan from Silicon Valley Bank (“SVB”). The Company will initially draw down US$1.5 million of the facility, and a further US$1.0
February 13, 2014	EX-10	LOAN AGREEMENT ex10-1.htm Exhibit 10.1 LOAN AGREEMENT THIS LOAN AGREEMENT (this “Agreement”) dated as of February 11, 2014 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and RESPONSE BIOMEDICAL CORP., a British Columbia corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows: 1. ACCOUNTIN
February 13, 2014	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant - FORM 8-K rpbif201402138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 11, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
February 13, 2014	EX-10	SECURITY AGREEMENT EX-10 3 ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 EXECUTION VERSION SECURITY AGREEMENT THIS SECURITY AGREEMENT is made the 11th day of February, 2014. BETWEEN: Response Biomedical Corp., a British Columbia corporation having its chief executive office at 1781 West 75th Avenue, Vancouver, British Columbia V6P 6P2 Facsimile: (604) 456-6066 (the “Debtor”) AND: SILICON VALLEY BANK, a California corporation
January 3, 2014	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K rpbif201401038k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 2, 2014 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
January 3, 2014	EX-99	Response Biomedical Corp. Provides Update on Chinese Distribution Agreement with O&D Biotech Co., Ltd. EX-99 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Response Biomedical Corp. Provides Update on Chinese Distribution Agreement with O&D Biotech Co., Ltd. Vancouver, British Columbia, January 2, 2014 – Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) today announced that its existing Chinese Distribution Agreement with O&D Biotech Co., Ltd. (“O&D”) dated February 21, 2011,
December 12, 2013	EX-24	LIMITED POWER OF ATTORNEY – SECURITIES LAW COMPLIANCE hollerpoa.htm LIMITED POWER OF ATTORNEY – SECURITIES LAW COMPLIANCE The undersigned, as a Section 16 reporting person of Response Biomedical Corp. (the “Company”), hereby constitutes and appoints Jeffrey L. Purvin, Peter A. Thompson, Anastasios Tsonis, and William J. Adams and each of them, the undersigned’s true and lawful attorneys-in-fact and agent to: 1. complete and execute such Forms 144, Fo
November 27, 2013	EX-99	Response Biomedical Corp. Announces Expansion of Chinese Distribution for RAMP® Cardiovascular Products ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Expansion of Chinese Distribution for RAMP® Cardiovascular Products Vancouver, British Columbia, November 25, 2013 – Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into agreements to distribute its Cardiovascular portfolio of RAMP® products with two new distributors in
November 27, 2013	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 25, 2013 RESPONSE BIOMEDICAL CORP.
November 15, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K rpbif201311158k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 13, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 15, 2013	EX-99	Response Biomedical Corp. Announces 2013 Third Quarter Financial Results ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces 2013 Third Quarter Financial Results VANCOUVER, British Columbia – November 13, 2013 - Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the quarter and nine months ended September 30, 2013. The Company reported sales of $2.1 million in the third quarter of 2013, a 22% de
November 13, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q rpbif2013093010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2013  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb
November 12, 2013	SC 13D/A	RPBIF / Response Biomedical Corp. / ORBIMED ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 12, 2013	EX-99.1	JOINT FILING AGREEMENT EX-99.1 Exhibit M JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated August 9, 2010, as amended by Amendment No. 1 to Schedule 13D originally filed on October 4, 2010, Amendment No. 2 to Schedule 13D originally filed on October 22, 2010, Amendment No. 3 to Schedule 13D originally filed on January 13, 2011, Amendment No. 4 to Schedule 13D originally filed
November 8, 2013	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders - FORM 8-K rpbif201311078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
November 8, 2013	EX-99	Response Biomedical Corp. Announces Conversion of Subscription Receipts ex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Conversion of Subscription Receipts VANCOUVER, British Columbia – November 7, 2013 - Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) is pleased to announce that shareholders of Response have approved the conversion of 1,273,117 subscription receipts (the “Subscription Receipts”) for gross proceeds of appro
October 15, 2013	DEF 14A	- FORM DEF 14A rpbif20131003def14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
September 26, 2013	EX-99	agency Agreement rbmv6.htm Exhibit 99.1 agency Agreement September 26, 2013 Response Biomedical Corp. 75th Avenue West, Suite 1781 Vancouver, British Columbia V6P 6P2 Attention: Jeffrey L. Purvin, Chief Executive Officer Gentlemen: Bloom Burton & Co. Inc. (the “Agent”) understands that Response Biomedical Corp. (the “Corporation”) proposes to issue and sell up to 816,326 subscription receipts (the “Subscription Re
September 26, 2013	EX-99	Response Biomedical Corp. Announces Brokered and Non-Brokered Private Placements of Subscription Receipts EX-99 6 ex99-5.htm EXHIBIT 99.5 Exhibit 99.5 Response Biomedical Corp. Announces Brokered and Non-Brokered Private Placements of Subscription Receipts VANCOUVER, British Columbia – September 26, 2013 - Response Biomedical Corp. (“Response” or the “Company”) (TSX: RBM, OTCBB: RPBIF) is pleased to announce the brokered and non-brokered private placement of Subscription Receipts for aggregate gross p
September 26, 2013	EX-99	SUBSCRIPTION RECEIPT AGREEMENT Providing for the Issue of up to 1,632,653 Subscription Receipts RESPONSE BIOMEDICAL CORP. - and – COMPUTERSHARE TRUST COMPANY OF CANADA - and – BLOOM BURTON & CO. INC. Dated as of September 26, 2013 TABLE OF CONTENTS ex99-3.htm Exhibit 99.3 SUBSCRIPTION RECEIPT AGREEMENT Providing for the Issue of up to 1,632,653 Subscription Receipts BETWEEN RESPONSE BIOMEDICAL CORP. - and – COMPUTERSHARE TRUST COMPANY OF CANADA - and – BLOOM BURTON & CO. INC. Dated as of September 26, 2013 TABLE OF CONTENTS Page Article I INTERPRETATION 2 1.1 Definitions 2 1.2 Gender and Number 6 1.3 Interpretation not Affected by Headings,
September 26, 2013	EX-99	RESPONSE BIOMEDICAL CORP. (THE “ISSUER”) PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT FOR SUBSCRIPTION RECEIPTS INSTRUCTIONS TO PURCHASER rbmv11.htm Exhibit 99.2 RESPONSE BIOMEDICAL CORP. (THE “ISSUER”) PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT FOR SUBSCRIPTION RECEIPTS INSTRUCTIONS TO PURCHASER 1. All purchasers must complete all the information in the boxes on page 2 and sign where indicated with an “X”. 2. If you are purchasing less than $150,000 and are an “accredited investor”, then complete and sign the “Accredited Investor For
September 26, 2013	EX-99	PRIVATE PLACEMENT LETTER AGREEMENT rbmv3.htm Exhibit 99.4 PRIVATE PLACEMENT LETTER AGREEMENT This letter agreement (this “Letter Agreement”) is entered into as of September 26, 2013, by and among Response Biomedical Corp., a British Columbia Corporation (“Response”), OrbiMed Private Investments III, LP, a Delaware limited partnership (“OrbiMed Investments”), OrbiMed Asia Partners, LP, a Cayman Islands limited partnership (“OrbiMed
September 26, 2013	PRE 14A	- FORM PRE 14A rpbif20130924pre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
September 26, 2013	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events rpbif201309248k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 26, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 91-1042523 (State or
August 13, 2013	EX-99	Response Biomedical Corp. Announces 2013 Second Quarter Financial Results ex99-1.htm Exhibit 99.1 AUGUST 13, 2013 Response Biomedical Corp. Announces 2013 Second Quarter Financial Results VANCOUVER, British Columbia – August 13, 2013 - Response Biomedical Corp. (“Response”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the quarter and six months ended June 30, 2013. The Company reported sales of $2.7 million in the second quarter of 2013, a 10% decline f
August 13, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K rpbif201308138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 13, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or o
August 13, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q rpbif2013063010q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2013 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
July 30, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K rpbif201307308k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 26, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or oth
July 30, 2013	EX-10	SEPARATION AGREEMENT AND MUTUAL RELEASE ex10-1.htm Exhibit 10.1 SEPARATION AGREEMENT AND MUTUAL RELEASE THIS AGREEMENT made on the 26th day of July, 2013 BETWEEN: RESPONSE BIOMEDICAL CORP. (the “Company”) AND: PATRICIA MASSITTI (“Massitti”) WHEREAS: A. The Company employed Massitti in the capacity of Vice President of Human Resources & Corporate Communications since September 14, 2009. B. The Company and the Employee have mutually agree
June 20, 2013	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K rpbif20130619b8k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 18, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or ot
June 20, 2013	EX-99	Response Biomedical Corp. Announces Voting Results rpbif20130619b8kex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Voting Results VANCOUVER, British Columbia – June 19, 2013 - Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) (the “Company”), in accordance with the requirements of the Toronto Stock Exchange, is pleased to announce the results of voting at its 2013 Annual General and Special Meeting of Shareholders held on June 18, 201
June 20, 2013	S-8	- FORM S-8 rpbif20130619s8.htm As filed with the Securities and Exchange Commission on June 19, 2013 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESPONSE BIOMEDICAL CORP. (Exact name of Registrant as specified in its charter) Vancouver, British Columbia, Canada 98 -1042523 (State or other jurisdiction o
June 20, 2013	EX-10	RESPONSE BIOMEDICAL CORP. NON-EMPLOYEE DIRECTORS DEFERRED SHARE UNIT PLAN Effective June 18, 2013 RESPONSE BIOMEDICAL CORP. NON-EMPLOYEE DIRECTORS DEFERRED SHARE UNIT PLAN rpbif20130619b8kex10-3.htm Exhibit 10.3 RESPONSE BIOMEDICAL CORP. NON-EMPLOYEE DIRECTORS DEFERRED SHARE UNIT PLAN Effective June 18, 2013 RESPONSE BIOMEDICAL CORP. NON-EMPLOYEE DIRECTORS DEFERRED SHARE UNIT PLAN 1. PURPOSE OF THE PLAN 1.1 This Plan has been established by the Corporation to promote the interests of the Corporation by attracting and retaining qualified persons to serve on the Board
June 20, 2013	EX-10	RESPONSE BIOMEDICAL CORP. AMENDED AND RESTATED 2008 STOCK OPTION PLAN Effective Date: June 18, 2013 rpbif20130619b8kex10-1.htm Exhibit 10.1 RESPONSE BIOMEDICAL CORP. AMENDED AND RESTATED 2008 STOCK OPTION PLAN Effective Date: June 18, 2013 2008 Stock Option Plan approved by the Board of Directors on June 3, 2008. 2008 Stock Option Plan approved by the Shareholders on June 3, 2008. Amendment the 2008 Stock Option Plan approved by the Shareholders on June 19, 2012. Approved by the Board of Directo
June 20, 2013	EX-10	RESPONSE BIOMEDICAL CORP. RESTRICTED SHARE UNIT PLAN Effective June 18, 2013 RESPONSE BIOMEDICAL CORP. RESTRICTED SHARE UNIT PLAN rpbif20130619b8kex10-2.htm Exhibit 10.2 RESPONSE BIOMEDICAL CORP. RESTRICTED SHARE UNIT PLAN Effective June 18, 2013 RESPONSE BIOMEDICAL CORP. RESTRICTED SHARE UNIT PLAN 1. PURPOSE 1.1 This Plan has been established by the Corporation to assist the Corporation in the recruitment and retention of highly qualified employees and consultants by providing a means to reward superior performance, to moti
May 17, 2013	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
May 14, 2013	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2013 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 Response Bi
May 14, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K rpbif201305138k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 13, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or othe
May 14, 2013	EX-99	Response Biomedical Corp. Announces 2013 First Quarter Financial Results rpbif201305138kex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces 2013 First Quarter Financial Results VANCOUVER, British Columbia – May 13, 2013 - Response Biomedical Corp. (“Response”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the quarter ended March 31, 2013. “We are pleased to report our financial results for the first quarter of 2013, which show continued revenue
March 15, 2013	EX-21	List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 15, 2013 Exhibit 21 List of Worldwide Subsidiaries of Response Biomedical Corp. as of March 15, 2013 Structure of ownership and control: Response Biomedical Corp. wholly owns the below mentioned entity. Subsidiary Name Jurisdiction of Organization Response Point of Care Inc. Delaware
March 15, 2013	10-K	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50571 RESPONSE BIOMEDICAL CORP. (E
March 13, 2013	EX-99	Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2012 Financial Results rpbif201303128kex99-1.htm Exhibit 99.1 Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2012 Financial Results VANCOUVER, British Columbia – March 11, 2013 - Response Biomedical Corp. (“Response”) (TSX: RBM, OTCBB: RPBIF) today reported financial results for the fourth quarter and year ended December 31, 2012. “We are encouraged by our financial results for the fourth quarter and year
March 13, 2013	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 11, 2013 RESPONSE BIOMEDICAL CORP.
March 1, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K rpbif201303018k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 26, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
March 1, 2013	EX-99	Response Biomedical Corp. announces the hire of Mr. Darby L. Darilek as Director of U.S. Sales to expand its presence and commitment to the U.S. market rpbif201303018kex99-1.htm Exhibit 99.1 Response Biomedical Corp. announces the hire of Mr. Darby L. Darilek as Director of U.S. Sales to expand its presence and commitment to the U.S. market Vancouver, British Columbia, February 26, 2013 – Response Biomedical Corp. (“Response, or the Company”) (TSX: RBM, OTCBB: RPBIF) is pleased to announce that Mr. Darby L. Darilek joined the Company on February
January 25, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K rpbif201301258k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 24, 2013 RESPONSE BIOMEDICAL CORP. (Exact name of registrant as specified in its charter) Vancouver, British Columbia, Canada 000-50571 98 -1042523 (State or
January 25, 2013	EX-99	Response Biomedical Corp. announces execution of new distribution agreement with Fisher HealthCare for U.S. Distribution of its Response Infectious Disease Products rpbif201301258kex99-1.htm Exhibit 99.1 Response Biomedical Corp. announces execution of new distribution agreement with Fisher HealthCare for U.S. Distribution of its Response Infectious Disease Products Vancouver, British Columbia, January 24, 2013 – Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) (Response) announced today that it has entered into a new nonexclusive distribution agreement wit
January 4, 2013	EX-99.1	Response Biomedical Corp. Announces Expansion of U.S. Distribution for RAMP® Cardiovascular Products Exhibit 99.1 Response Biomedical Corp. Announces Expansion of U.S. Distribution for RAMP® Cardiovascular Products Vancouver, British Columbia, January 3, 2013 – Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) today announced that it has entered into a distribution agreement with Laboratory Supply Company, Inc. (LABSCO), a leading distributor of innovative diagnostic technologies and laboratory
January 4, 2013	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 3, 2013 RESPONSE BIOMEDICAL CORP.
November 15, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 14, 2012 RESPONSE BIOMEDICAL CORP.
November 15, 2012	EX-99.1	Response Biomedical Corp. Announces Third Quarter 2012 Financial Results Exhibit 99.1 Response Biomedical Corp. Announces Third Quarter 2012 Financial Results VANCOUVER, British Columbia – November 14, 2012 - Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) today reported financial results for the three and nine months ended September 30, 2012. “We are encouraged by our financial results for the quarter, which show continued revenue growth and strengthening of our gr
November 14, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 Respons
November 9, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 7, 2012 RESPONSE BIOMEDICAL CORP.
November 9, 2012	EX-99.1	Response Biomedical Corp. Announces the CE Mark of D-dimer Assay for the EU Market Exhibit 99.1 Response Biomedical Corp. Announces the CE Mark of D-dimer Assay for the EU Market FOR IMMEDIATE RELEASE VANCOUVER, British Columbia – November 7, 2012 - Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) announced today that the Company has received CE Mark for their D-dimer Point of Care (“POC”) assay for the European market. The D-dimer assay is part of the menu expansion for the R
October 5, 2012	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 3 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50
October 5, 2012	10-Q/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000
October 4, 2012	8-K	Termination of a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 2, 2012 RESPONSE BIOMEDICAL CORP.
October 4, 2012	EX-99.1	Response Biomedical Corporation Announces Acquisition of Worldwide Rights of Infectious Disease Testing due to Termination of 3M Agreements Exhibit 99.1 Response Biomedical Corporation Announces Acquisition of Worldwide Rights of Infectious Disease Testing due to Termination of 3M Agreements VANCOUVER, British Columbia – October 2, 2012 Response Biomedical Corp. (TSX: RBM, OTCBB: RPBID) (the “Company” or “Response”), announced today it has regained the worldwide rights to Flu A+B and RSV testing products as a result of the termination
September 27, 2012	CORRESP	- rpbif20120927corresp.htm 1781 75th Avenue W Vancouver BC Canada V6P 6P2 Tel:604.456.6010 Fax:604.456.6066 www.responsebio.com September 27, 2012 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tia L. Jenkins, Senior Assistant Chief Accountant Office of Beverages, Apparel and Mining Re: Response Biomedic
September 25, 2012	EX-99.1	Response Biomedical Corp. Announces Share Consolidation EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Response Biomedical Corp. Announces Share Consolidation Vancouver, British Columbia – September 24, 2012 - Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) (the “Company” or “Response”), announced today the completion of the consolidation of issued and outstanding common shares of the Company (the “Common Shares”) on the basis of every twenty (20) C
September 25, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 24, 2012 RESPONSE BIOMEDICAL CORP.
September 11, 2012	CORRESP	- 1781 75th Avenue W Vancouver BC Canada V6P 6P2 Tel: 604.456.6010 Fax: 604.456.6066 www.responsebio.com September 11, 2012 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attn: Tia L. Jenkins, Senior Assistant Chief Accountant Office of Beverages, Apparel and Mining Re: Response Biomedical Corporation Form 10-
August 20, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 16, 2012 RESPONSE BIOMEDICAL CORP.
August 20, 2012	EX-99.1	Response Biomedical Corporation Announces Share Consolidation Response Biomedical Corporation Announces Share Consolidation VANCOUVER, British Columbia - August 16, 2012 - Response Biomedical Corp.
August 20, 2012	S-8	- FORM S-8 As filed with the Securities and Exchange Commission on August 20, 2012 File No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RESPONSE BIOMEDICAL CORP. (Exact name of Registrant as specified in its charter) Vancouver, British Columbia, Canada 98 -1042523 (State or other jurisdiction of incorporation or
August 10, 2012	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of June 28th, 2012. BETWEEN: RESPONSE BIOMEDICAL CORP. (the “Company”), having an office at 1781 West 75th Ave., Vancouver, BC, Canada V6P 6P2, AND W.J. Bill Adams, (the “Executive”), having a residence at Vancouver, BC WHEREAS: A. The Company wishes to employ the Executive in the position of Chief Financial Officer (“
August 10, 2012	EX-99.1	Response Biomedical Corporation Announces Appointment of W.J. (Bill) Adams as CFO & Corporate Secretary and Resignation of Richard A. Canote as CFO Exhibit 99.1 Response Biomedical Corporation Announces Appointment of W.J. (Bill) Adams as CFO & Corporate Secretary and Resignation of Richard A. Canote as CFO VANCOUVER, British Columbia – August 9, 2012 – Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) (the “Company”) today reported that the Board of Directors of the Company has appointed Mr. Bill Adams as Chief Financial Officer (“CFO
August 10, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 9, 2012 RESPONSE BIOMEDICAL CORP.
August 9, 2012	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-50571 Response Bio
August 8, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 7, 2012 RESPONSE BIOMEDICAL CORP.
August 8, 2012	EX-99.1	Response Biomedical Corporation Announces Second Quarter 2012 Financial Results Exhibit 99.1 Response Biomedical Corporation Announces Second Quarter 2012 Financial Results VANCOUVER, British Columbia – August 7, 2012 - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today reported financial results for the three and six months ended June 30, 2012. Financial results for the three months ended June 30, 2012 · Product sales of $3.0 million for the three months ended Ju
July 30, 2012	EX-99.1	Response Biomedical Corporation Announces Appointment of Dr. Jonathan Wang as Director Exhibit 99.1 Response Biomedical Corporation Announces Appointment of Dr. Jonathan Wang as Director DRAFT FOR IMMEDIATE RELEASE VANCOUVER, British Columbia – July 30, 2012 - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) (the “Company”) today reported that effective July 25, 2012, the Board of Directors of the Company have appointed Jonathan Wang, Ph.D. as a Director. Dr. Wang was a prev
July 30, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2012 RESPONSE BIOMEDICAL CORP.
July 27, 2012	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of April 10, 2012. BETWEEN: RESPONSE BIOMEDICAL CORPORATION (the “Company”), having an office at 1781 West 75th Avenue. Vancouver, BC, Canada V6P 6P2, AND Jeffrey L. Purvin, (the “Executive”), having a residence at 21 Sandstone, Portola Valley, CA 94028 WHEREAS: A. The Company wishes to employ the Executive in the posi
July 27, 2012	EX-99.1	Appointment of Jeffrey L. Purvin as Director & CEO and Resignation of Peter Thompson as Interim CEO Exhibit 99.1 Response Biomedical Corporation Announces Appointment of Jeffrey L. Purvin as Director & CEO and Resignation of Peter Thompson as Interim CEO VANCOUVER, British Columbia – July 25, 2012 - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today reported that effective July 25, 2012, the Board of Directors of the Company has appointed Mr. Jeffrey L. Purvin as a Director and Chief
July 27, 2012	EX-99.2	Response Biomedical Corp. Announces New Hire Mr. Tim Shannon as Senior Vice President, World Wide Sales & Marketing EX-99.2 5 ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Response Biomedical Corp. Announces New Hire Mr. Tim Shannon as Senior Vice President, World Wide Sales & Marketing FOR IMMEDIATE RELEASE VANCOUVER, British Columbia – July 26, 2012 - Response Biomedical Corp. (TSX: RBM, OTCBB: RPBIF) is pleased to announce Mr. Tim Shannon joined Response on July 25th, 2012 as Senior Vice President, World Wide Sales a
July 27, 2012	EX-10.2	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT is made effective as of June 28, 2012. BETWEEN: RESPONSE BIOMEDICAL CORP. (the “Company”), having an office at 1781 West 75th Avenue, Vancouver, BC, Canada V6P 6P2, AND Tim Shannon (the “Executive”), having a residence in Charlotte, North Carolina, USA. WHEREAS: A. The Company wishes to employ the Executive in the position of Senior Vice P
July 27, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 25, 2012 RESPONSE BIOMEDICAL CORP.
June 29, 2012	EX-10.1	CONSULTING AGREEMENT Exhibit 10.1 CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (the "Agreement") dated as of the 20th day of June, 2012 (the "Effective Date"). BETWEEN: RESPONSE BIOMEDICAL CORP., a British Columbia corporation with an address at 1781 – 75th Avenue West, Vancouver, BC V6P 6P2 (hereinafter referred to as “Response”) AND: Jeffrey L. Purvin, a management consultant, having a residence at 21 Sandstone, P
June 29, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2012 RESPONSE BIOMEDICAL CORP.
June 25, 2012	EX-10.1	RESPONSE BIOMEDICAL CORP. 2008 STOCK OPTION PLAN Effective Date: June 3, 2008 EX-10.1 2 ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 RESPONSE BIOMEDICAL CORP. 2008 STOCK OPTION PLAN Effective Date: June 3, 2008 Approved by the Board of Directors on June 3, 2008. Approved by the Shareholders on June 3, 2008. Amendment approved by the Shareholders on June 19, 2012 TABLE OF CONTENTS SECTION 1 DEFINITIONS AND INTERPRETATION 4 1.1 Definitions 4 1.2 Choice of Law 8 1.3 Headings 8 SECTION
June 25, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 19, 2012 RESPONSE BIOMEDICAL CORP.
May 23, 2012	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State
May 18, 2012	CORRESP	- May 18, 2012 Via EDGAR & Overnight Delivery U.S. Securities and Exchange Commission Division of Corporate Finance 100 F Street, NE Washington, DC 20549 Re: Response Biomedical Corporation Schedule 14A Filed May 3, 2012 File No. 000-50571 Ladies and Gentleman: Response Biomedical Corporation, or the Company, provides this response to the comments of the staff (“Staff”) of the United States Securiti
May 18, 2012	PRER14A	- PRER14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State
May 16, 2012	10-K/A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 2 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-50
May 16, 2012	EX-10.31	INTERNATIONAL DISTRIBUTION AGREEMENT Exhibit 10-31 INTERNATIONAL DISTRIBUTION AGREEMENT THIS DISTRIBUTION AGREEMENT by and between Response Biomedical Corporation, of 1781 - 75th Avenue W.
May 8, 2012	EX-99.1	Response Biomedical Corporation Announces First Quarter 2012 Financial Results EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Response Biomedical Corporation Announces First Quarter 2012 Financial Results VANCOUVER, British Columbia – May 7, 2012 - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) today reported financial results for the three months ended March 31, 2012. Financial results for the period ended March 31, 2012 · Product sales of $2.98 million for the th

RPBIF / Response Biomedical Corp. - Documents déposés auprès de la SEC, rapport annuel, procuration

Statistiques de base

SEC Filings

SEC Filings (Chronological Order)